THE HUMAN IMMUNE SYSTEM
TRANSFUSION
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
|
|
Day Raid Cursed Undead CD20 +
|
|
|
increasing doses of MTX regardless of age?
|
|
|
increasing doses of MTX in patients <45 years?
|
|
|
For high-risk patients: blinatumomab for B-ALL
|
Detailed explanation-1: -A single cycle of treatment of BLINCYTO induction or consolidation consists of 28 days of continuous intravenous infusion followed by a 14-day treatment-free interval (total 42 days). to 45 kg receive a fixed-dose. For patients less than 45 kg, the dose is calculated using the patient’s body surface area (BSA).
Detailed explanation-2: -Immunotherapy (monoclonal antibodies or CAR T-cell therapy) may be an option for patients with B-cell ALL. A stem cell transplant may be tried if the leukemia can be put into at least partial remission. Clinical trials of new treatment approaches may also be considered.
Detailed explanation-3: -The results showed patients who received blinatumomab plus chemotherapy during the consolidation phase fared significantly better, with an overall survival rate of 83% compared with 65% among patients receiving consolidation chemotherapy alone.
Detailed explanation-4: -What’s B-cell acute lymphoblastic leukemia? B-cell acute lymphoblastic leukemia (B-ALL) happens when the bone marrow produces too many abnormal B-lymphocytes, a type of white blood cell that helps your body fight infection.